TABLE 2. Postoperative Characteristics of the Patient Cohort.
| PSA of 50-99 ng/mL (n=178) |
PSA ≥100 ng/mL (n=56) |
Overall (n=234) |
|
|---|---|---|---|
| Pathologic Gleason score | |||
| ≤6 | 42 (25%) | 16 (32%) | 58 (26%) |
| 7 | 86 (50%) | 23 (45%) | 109 (49%) |
| 8-10 | 43 (25%) | 12 (24%) | 55 (25%) |
| 1997 TNM pathologic stage | |||
| T2a | 8 (5%) | 1 (2%) | 9 (4%) |
| T2b | 27 (15%) | 4 (7%) | 31 (13%) |
| T3/4 | 143 (80%) | 51 (91%) | 194 (83%) |
| Seminal vesicles | |||
| Positive | 112 (63%) | 46 (82%) | 158 (68%) |
| Negative | 66 (37%) | 10 (18%) | 76 (33%) |
| Pelvic lymph nodes | |||
| Positive | 62 (35%) | 24 (43%) | 86 (37%) |
| Negative | 116 (65%) | 32 (57%) | 148 (63%) |
| Surgical margins | |||
| Positive | 139 (78%) | 46 (82%) | 185 (79%) |
| Negative | 39 (22%) | 10 (18%) | 49 (21%) |
| Adjuvant EBRT | |||
| Yes | 31 (17%) | 8 (14%) | 39 (17%) |
| No | 147 (83%) | 48 (86%) | 195 (83%) |
| Adjuvant ADT | |||
| Yes | 99 (56%) | 39 (70%) | 138 (59%) |
| No | 79 (44%) | 17 (30%) | 96 (41%) |
| Salvage EBRT | |||
| Yes | 34 (19%) | 9 (16%) | 43 (21%) |
| No | 144 (81%) | 47 (84%) | 191 (79%) |
| Salvage ADT | |||
| Yes | 62 (35%) | 18 (32%) | 80 (34%) |
| No | 116 (65%) | 38 (68%) | 154 (66%) |
PSA indicates prostate-specific antigen; EBRT, external beam radiotherapy; ADT, androgen deprivation therapy.